(e,z)-farnesol

(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 | Total 23

PubChem Biomolecular Interactions and Pathways

All references with (e,z)-farnesol

Download all related citations
Per page 10 20 50 100 | Total 813
Authors Title Published Journal PubMed Link
Rocha GR et al. Effect of tt-farnesol and myricetin on in vitro biofilm formed by Streptococcus mutans and Candida albicans. 2018 BMC Complement Altern Med pmid:29444673
Jeon JG et al. Influences of naturally occurring agents in combination with fluoride on gene expression and structural organization of Streptococcus mutans in biofilms. 2009 BMC Microbiol. pmid:19863808
Cerca N et al. Confocal laser scanning microscopy analysis of S. epidermidis biofilms exposed to farnesol, vancomycin and rifampicin. 2012 BMC Res Notes pmid:22591918
Langman MJ et al. Treatment of chronic gastric ulcer with carbenoxolone and gefarnate: a comparative trial. 1973 Br Med J pmid:4577839
Alves FR et al. Antibiofilm and antibacterial activities of farnesol and xylitol as potential endodontic irrigants. 2013 Braz Dent J pmid:23969910
Alves FR et al. Biofilm biomass disruption by natural substances with potential for endodontic use. 2013 Jan-Feb Braz Oral Res pmid:23306623
Journe F et al. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. 2008 Breast Cancer Res. Treat. pmid:17333335
Still K et al. Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. 2003 Calcif. Tissue Int. pmid:12457261
Braun PC The effect of farnesol on amino acid incorporation by a wild-type and cell-wall variant strain of Candida albicans. 2005 Can. J. Microbiol. pmid:16234870
Tsimberidou AM et al. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. 2010 Cancer Chemother. Pharmacol. pmid:19484470
Haklai R et al. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. 2008 Cancer Chemother. Pharmacol. pmid:17909812
Au-Yeung KK et al. Herbal isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPARgamma. 2008 Cancer Invest. pmid:18608213
Joo JH and Jetten AM Molecular mechanisms involved in farnesol-induced apoptosis. 2010 Cancer Lett. pmid:19520495
Mo H et al. Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanomas. 2000 Cancer Lett. pmid:10936674
Yazlovitskaya EM and Melnykovych G Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. 1995 Cancer Lett. pmid:7874691
Adany I et al. Differences in sensitivity to farnesol toxicity between neoplastically- and non-neoplastically-derived cells in culture. 1994 Cancer Lett. pmid:8019976
McAnally JA et al. Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells. 2003 Cancer Lett. pmid:14643448
Shipman CM et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. 1998 Cancer Res. pmid:9850051
Blum R et al. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). 2007 Cancer Res. pmid:17409441
Blum R et al. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. 2005 Cancer Res. pmid:15705901

Table of Content